Novavax inc (NVAX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenue:
Grant and other

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Government contract

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,253

12,458

26,044

33,344

35,269

36,466

29,987

26,213

26,940

23,704

19,739

17,708

14,328

15,643

19,470

20,671

23,173

22,598

18,496

14,688

9,018

4,017

0

0

0

Research and development collaborations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,553

6,642

4,547

-

1,853

2,345

3,087

4,446

5,744

5,568

4,805

3,207

2,404

2,052

1,797

1,405

182

0

0

-

0

-

-

-

-

Total revenue

18,057

18,662

15,973

21,201

28,617

34,288

38,573

39,190

35,149

31,176

26,163

21,042

16,815

15,353

15,806

19,100

30,591

36,250

37,122

38,811

33,074

30,659

32,684

29,272

24,544

20,915

16,732

17,695

21,267

22,076

22,518

0

0

-

0

-

-

-

-

Expenses:
Cost of government contracts revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

7,570

9,132

12,618

14,692

15,981

14,333

10,446

7,003

0

0

0

-

-

Research and development

95,264

113,842

127,916

150,631

164,756

173,797

180,038

180,574

175,295

168,435

169,879

181,000

206,641

237,939

262,743

240,424

203,249

162,644

132,223

120,778

108,251

94,422

73,480

68,209

63,792

58,530

43,545

36,239

30,825

26,907

22,242

19,649

18,631

18,364

21,343

23,621

0

0

0

Gain on Catalent transaction

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

35,064

34,417

35,461

35,871

34,489

34,409

33,726

33,535

34,251

34,451

34,254

39,692

44,851

46,527

47,034

42,538

35,527

30,842

27,048

22,745

21,463

19,928

18,951

18,051

16,257

14,819

13,293

11,570

10,027

10,142

9,563

10,166

11,035

10,900

11,769

12,180

0

0

0

Total expenses

121,312

139,243

154,361

186,502

199,245

208,206

213,764

214,109

209,546

202,886

204,133

220,692

251,492

284,466

309,777

282,962

238,776

193,486

147,121

135,400

126,693

114,350

98,961

91,039

81,358

73,349

64,408

56,941

53,470

51,741

47,786

44,148

40,112

36,267

36,876

37,375

0

0

0

Loss from operations

-103,255

-120,581

-138,388

-165,301

-170,628

-173,918

-175,191

-174,919

-174,397

-171,710

-177,970

-199,650

-234,677

-269,113

-293,971

-263,862

-208,185

-157,236

-109,999

-96,589

-93,619

-83,691

-66,277

-61,767

-56,814

-52,434

-47,676

-39,246

-32,203

-29,665

-24,431

-21,550

-21,616

-21,579

-27,858

-33,358

0

0

0

Other income (expense):
Investment income

1,528

1,512

1,820

2,230

2,563

2,674

2,508

2,287

2,003

1,946

1,974

1,997

2,144

2,143

1,908

1,548

1,012

660

575

509

395

286

198

123

151

187

203

189

180

165

141

124

123

136

156

178

0

0

0

Interest expense

13,612

13,612

13,612

13,612

13,612

13,612

13,732

13,849

13,962

14,072

14,061

14,052

14,048

12,965

9,568

6,121

2,635

241

133

116

141

157

179

196

190

160

151

93

51

32

15

11

10

9

8

8

0

0

0

Other income (expense)

-

-13

-18

-42

63

108

158

187

89

67

22

23

13

-31

-32

-94

-11

-120

-120

-88

-142

0

-11

8

0

-

0

0

-

-

0

-

-

-

-

-

-

-

-

Realized gains on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

615

615

615

615

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-101

100

1,237

2,642

2,474

2,106

1,939

0

0

0

Loss from operations before income tax expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-51,958

-45,941

-37,858

-31,150

-28,507

-23,685

-21,049

0

-

0

0

-

0

0

Income tax expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

22

22

17

0

0

412

0

-

0

0

-

0

0

Net loss

-115,340

-132,694

-150,198

-176,725

-181,614

-184,748

-186,257

-186,294

-186,267

-183,769

-190,035

-211,682

-246,568

-279,966

-301,663

-268,529

-209,819

-156,937

-109,677

-96,284

-93,507

-82,947

-65,455

-61,028

-55,797

-51,983

-45,963

-37,880

-31,167

-28,507

-24,179

-20,174

-19,247

-19,364

-25,880

-31,525

0

0

0

Basic and diluted net loss per share

-0.58

-0.97

-0.74

-1.69

-2.11

-5.15

-2.33

-2.37

-0.14

-12.09

-0.15

-0.16

-0.16

-0.21

-0.24

-0.29

-0.29

-0.30

-0.12

-0.08

-0.10

-0.14

-0.08

-0.08

-0.07

-0.07

-0.09

-0.08

-0.07

-0.06

-0.05

-0.05

-0.06

-0.03

-0.03

-0.04

-0.07

-0.10

-0.09

Basic and diluted weighted average number of common shares outstanding

44,421

28,158

24,327

23,473

20,442

-300,932

19,116

18,796

336,972

-521,621

296,435

283,444

274

1,082,395

271

270

270

-240,711

269

268

241,223

-454,787

238,304

217,178

208

678,162

168

152

148

145

134

126

120

-223,669

115

112,821

111,188

107,092

100,694

Unrealized gains on short-term investments available-for-sale

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Grant and other [Member]
Total revenue

10,557

11,162

15,973

21,201

28,617

34,288

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-